Effective pain management WITHOUT dangerous OPIOIDS for chronic pain: CBD (cannabidiol) may be the answer
Most people are aware of the staggering opioid (opiate) crisis. A recent study projected that 1.2 million people in the U.S. and Canada will die from opioid overdoses unless there is urgent intervention. Since 1999, more than 600,000 people have died in North America and addictions are rising steadily in the United Kingdom, Netherlands and Israel.
This is a global problem – and the concern is that it’s irreversible. By now you’ve no doubt read about how some pharmaceutical companies, in the mid-1990s, began promoting drugs like OxyContin to treat chronic pain, glossing over, in unethical and misleading ways, just how insidiously addictive these drugs are.
And that’s the key issue at the heart of this crisis – pain, and especially chronic pain, can be intolerable. And pain comes in many forms, especially with an aging population: as many as 1 in 4 Canadians over age 50 battles chronic pain. It’s a leading cause of disability globally and is a major factor in reducing the quality of life, decreased social connections and lost productivity. Most people treating chronic pain start with acetaminophen (Tylenol) or NSAIDS (e.g. ibuprofen, naproxen, indomethacin, etc). However, if their pain is poorly controlled or worsens, higher doses of these drugs over a long period of time can cause serious GI side effects including bleeding. Most people and their doctors are left with little choice but to prescribe opioids for additional control of chronic pain.
But now, there is a safe, effective and non-addictive alternative for pain management that promises additional relief without turning to opioids’ vicious and addictive cycle: cannabinoids such as CBD for chronic pain relief from inflammatory conditions.
Cannabinoids are proven to play a role in relieving inflammatory and neuropathic pain. CBD (cannabidiol) and THC (tetrahydrocannabinol) are two common cannabinoids found in cannabis that control inflammation that causes pain and can help inhibit the sensation of pain. There’s accumulating evidence to support their safe use in treating chronic pain.
Opticann uses patented pharmaceutical technology, VESIsorb®, in its CB4 Relief-T softgels with 25 mg CBD, 13 mg BCP (a terpene with antinflammatory properties) and only 0.75 mg of THC.
CB4 Relief-T softgels are fast acting and long-lasting. VESIsorb® is clinically proven to increase absorption (potency) of CBD by 440% (4.4x) and enables 3 times faster onset of action than conventional CBD capsules.1 The low concentration of THC minimizes any possible side effects.
All Opticann CB4 products are developed with innovative pharmaceutical technology and are scientifically tested to provide maximum benefits, quickly. CB4 Relief-T capsules were clinically tested and the results published in a scientific peer reviewed journal. 1
1 Knaub, K. et al. (2019). A novel self-emulsifying drug delivery system (SEDDS) based on VESIsorb® formulation technology improving the oral bioavailability of cannabidiol in healthy subjects. Molecules, 24(16): 2967. https://doi.org/10.3390/molecules24162967